EDAP TMS Résultats passés
Passé contrôle des critères 0/6
Les bénéfices de EDAP TMS ont diminué à un taux annuel moyen de -49.6%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en à 13.6% par an. Les revenus ont augmenté de en à un taux moyen de 8.4% par an.
Informations clés
-49.63%
Taux de croissance des bénéfices
-49.17%
Taux de croissance du BPA
| Medical Equipment Croissance de l'industrie | 8.90% |
| Taux de croissance des recettes | 8.36% |
| Rendement des fonds propres | -305.76% |
| Marge nette | -41.70% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • May 21
EDAP: Reaffirmed 2026 Outlook Will Support Discount Rate Recalibration
Analysts have lowered their price target on EDAP TMS by $4, citing updated assumptions around the discount rate, revenue growth, profit margins and future P/E as key drivers of the change. Analyst Commentary Bullish analysts highlight that the revised price target, while reduced by US$4, still reflects confidence in EDAP TMS's ability to execute on its business plan and support a valuation that they view as attractive relative to updated assumptions.Mise à jour du récit • Apr 27
EDAP: Reaffirmed 2026 Revenue Guidance Will Support Refined Upside Thesis
Analysts have trimmed their price target on EDAP TMS by $4, citing updated assumptions around discount rates, revenue growth, and future P/E that refine their view of the company’s risk and earnings profile. Analyst Commentary Bullish analysts acknowledge the $4 trim to the price target as a recalibration to updated discount rate, revenue, and future P/E assumptions, rather than a change in their broader view of EDAP TMS.Mise à jour du récit • Apr 12
EDAP: Revised Outlook Will Rely On 2026 Revenue Guidance Execution
Analysts have lowered their price target on EDAP TMS to $10.00 from $14.00, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts lowering the price target to US$10.00 from US$14.00 reflects updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations rather than a single headline event.
Mise à jour du récit • Mar 29
EDAP: Longer Term Revenue Outlook Will Support Future Upside
Analysts have adjusted their price target on EDAP TMS to $6.83. The change reflects updated assumptions for discount rate, revenue growth, profit margin, and future P/E that are now more closely aligned with their current modeling for the business.
Mise à jour du récit • Mar 14
EDAP: 2026 Segment Guidance Will Limit Upside Versus Current Pricing
Analysts have adjusted their price target on EDAP TMS to reflect updated assumptions for revenue growth, profit margins, discount rate and future P/E. This has led to a revised valuation framework that investors should watch closely against the current share price in dollar terms.Mise à jour du récit • Feb 28
EDAP: 2026 Segment Guidance Will Constrain Future Share Price Upside
Analysts have lifted their EDAP TMS price target to reflect updated assumptions for a $2.50 fair value, a slightly higher discount rate, a shift from a 1.0% revenue decline to 20.8% growth expectations, a modestly stronger 13.40% profit margin outlook, and a lower forward P/E of about 11.6x. What's in the News EDAP TMS issued revenue guidance for 2026 for its HIFU business, with a range of $50.0 million to $54.0 million, or €43.0 million to €46.0 million.Mise à jour du récit • Feb 14
EDAP: Flat Revenue Outlook And Higher P/E Assumptions Will Limit Upside
Analysts have raised their $ fair value estimate for EDAP TMS from $1.50 to $2.50, citing updated assumptions that include a lower discount rate, a revenue growth outlook that is closer to flat, slightly higher profit margins, and a higher future P/E multiple. What's in the News Issued 2026 revenue guidance for the HIFU business in a range of $50.0 million to $54.0 million, or €43.0 million to €46.0 million (company guidance).Article d’analyse • Feb 03
EDAP TMS S.A. (NASDAQ:EDAP) Shares Fly 32% But Investors Aren't Buying For Growth
EDAP TMS S.A. ( NASDAQ:EDAP ) shares have continued their recent momentum with a 32% gain in the last month alone...Mise à jour du récit • Jan 31
EDAP: HIFU Guidance And FDA Clearance Will Support Future Upside
Analysts have adjusted their price target on EDAP TMS to US$25.18 from US$26.39, citing updated assumptions for the discount rate, profit margin and future P/E, which leave their fair value view broadly unchanged. What's in the News EDAP TMS issued 2026 revenue guidance, with HIFU business revenue expected in a range of US$50.0 million to US$54.0 million and non core Distribution and ESWL revenue in a range of US$22.0 million to US$26.0 million, also provided in euro terms as €43.0 million to €46.0 million and €19.0 million to €22.0 million respectively (company guidance).Mise à jour du récit • Jan 17
EDAP: Future Guidance And FDA Clearance Will Support Bullish Upside
Analysts now see higher upside for EDAP TMS, lifting their fair value estimate from about US$5.77 to roughly US$6.83 as they factor in slightly different assumptions around discount rate, revenue growth, profit margins and future P/E levels. What's in the News EDAP TMS issued 2026 revenue guidance, with HIFU business revenue expected in a range of US$50.0 million to US$54.0 million and non core Distribution and ESWL revenue in a range of US$22.0 million to US$26.0 million (Key Developments).Article d’analyse • Dec 20
EDAP TMS S.A.'s (NASDAQ:EDAP) Price Is Right But Growth Is Lacking After Shares Rocket 32%
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders would be excited to see that the share price has had a great month, posting...Article d’analyse • Dec 13
EDAP TMS (NASDAQ:EDAP) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Mise à jour du récit • Aug 29
CE Mark And Global Expansion Will Elevate HIFU Adoption
Despite a modest decline in consensus revenue growth forecasts, EDAP TMS’s sharply higher projected P/E multiple suggests increased investor optimism regarding future earnings quality or profitability, driving the analyst price target up from $5.75 to $14.00. What's in the News EDAP TMS raised its 2025 core HIFU business revenue growth guidance to 26%-34% year over year, up from the previous 16%-25% range.Article d’analyse • Aug 19
There Is A Reason EDAP TMS S.A.'s (NASDAQ:EDAP) Price Is Undemanding
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 0.8x might make it look like a strong buy right now...Article d’analyse • Jul 03
Is EDAP TMS (NASDAQ:EDAP) Using Debt Sensibly?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • May 18
Improved Revenues Required Before EDAP TMS S.A. (NASDAQ:EDAP) Stock's 28% Jump Looks Justified
Those holding EDAP TMS S.A. ( NASDAQ:EDAP ) shares would be relieved that the share price has rebounded 28% in the last...
Nouveau récit • Apr 08
CE Mark And Global Expansion Will Elevate HIFU Adoption
New approvals and strategic collaborations enhance EDAP TMS's market opportunities, potentially driving future revenue growth and improving margins.Article d’analyse • Apr 03
EDAP TMS S.A. (NASDAQ:EDAP) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders that were waiting for something to happen have been dealt a blow with a 27...Article d’analyse • Mar 15
Is EDAP TMS (NASDAQ:EDAP) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Article d’analyse • Dec 25
Potential Upside For EDAP TMS S.A. (NASDAQ:EDAP) Not Without Risk
With a price-to-sales (or "P/S") ratio of 1.2x EDAP TMS S.A. ( NASDAQ:EDAP ) may be sending very bullish signals at the...Article d’analyse • Oct 24
Is EDAP TMS (NASDAQ:EDAP) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Article d’analyse • Sep 07
Slammed 35% EDAP TMS S.A. (NASDAQ:EDAP) Screens Well Here But There Might Be A Catch
EDAP TMS S.A. ( NASDAQ:EDAP ) shareholders that were waiting for something to happen have been dealt a blow with a 35...Article d’analyse • Jul 24
Fewer Investors Than Expected Jumping On EDAP TMS S.A. (NASDAQ:EDAP)
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 2.6x might make it look like a buy right now...Article d’analyse • Mar 22
There's Reason For Concern Over EDAP TMS S.A.'s (NASDAQ:EDAP) Massive 28% Price Jump
Despite an already strong run, EDAP TMS S.A. ( NASDAQ:EDAP ) shares have been powering on, with a gain of 28% in the...Article d’analyse • Mar 03
Does EDAP TMS (NASDAQ:EDAP) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Jan 19
It's A Story Of Risk Vs Reward With EDAP TMS S.A. (NASDAQ:EDAP)
With a median price-to-sales (or "P/S") ratio of close to 3.2x in the Medical Equipment industry in the United States...Article d’analyse • Aug 11
Investors Still Waiting For A Pull Back In EDAP TMS S.A. (NASDAQ:EDAP)
EDAP TMS S.A.'s ( NASDAQ:EDAP ) price-to-sales (or "P/S") ratio of 4.7x might make it look like a sell right now...Article d’analyse • Dec 19
Is There An Opportunity With EDAP TMS S.A.'s (NASDAQ:EDAP) 20% Undervaluation?
Does the December share price for EDAP TMS S.A. ( NASDAQ:EDAP ) reflect what it's really worth? Today, we will estimate...Article d’analyse • Nov 23
EDAP TMS' (NASDAQ:EDAP) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for EDAP TMS S.A.'s ( NASDAQ:EDAP ) stock hasn't moved much. We did...Seeking Alpha • Sep 22
EDAP TMS stock falls 7% aftermarket on proposed ADS offering
EDAP TMS (NASDAQ:EDAP) stock fell ~7% postmarket after the company said it commenced a public offering of its American depositary shares, each representing one ordinary share. There can be no assurance as to whether or when the proposed offering may be completed or the actual size or terms.Seeking Alpha • Aug 24
EDAP TMS S.A. GAAP EPS of $0.06 beats by $0.09, revenue of $14.97M beats by $1.35M
EDAP TMS S.A. press release (NASDAQ:EDAP): Q2 GAAP EPS of $0.06 beats by $0.09. Revenue of $14.97M (+20.3% Y/Y) beats by $1.35M. 79% growth in HIFU revenues for the first half of 2022 compared to same period in 2021 Strong cash position of $48.5 million as of June 30, 2022 Company to host Focal One Expert User Panel event in New York City on Thursday, September 29.Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment EDAP TMS gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 74 | -31 | 48 | 10 |
| 31 Dec 25 | 71 | -29 | 45 | 10 |
| 30 Sep 25 | 75 | -23 | 46 | 10 |
| 30 Jun 25 | 74 | -25 | 47 | 10 |
| 31 Mar 25 | 68 | -23 | 43 | 9 |
| 31 Dec 24 | 69 | -21 | 43 | 8 |
| 30 Sep 24 | 71 | -25 | 39 | 9 |
| 30 Jun 24 | 66 | -21 | 36 | 9 |
| 31 Mar 24 | 65 | -20 | 34 | 8 |
| 31 Dec 23 | 67 | -23 | 37 | 8 |
| 30 Sep 23 | 60 | -22 | 37 | 6 |
| 30 Jun 23 | 62 | -19 | 36 | 6 |
| 31 Mar 23 | 62 | -12 | 32 | 6 |
| 31 Dec 22 | 59 | -3 | 25 | 5 |
| 30 Sep 22 | 52 | 3 | 21 | 4 |
| 30 Jun 22 | 53 | 3 | 21 | 4 |
| 31 Mar 22 | 52 | 0 | 20 | 4 |
| 31 Dec 21 | 50 | 1 | 19 | 4 |
| 30 Sep 21 | 53 | 0 | 18 | 4 |
| 30 Jun 21 | 54 | 0 | 17 | 5 |
| 31 Mar 21 | 52 | 0 | 16 | 4 |
| 31 Dec 20 | 51 | -2 | 17 | 5 |
| 30 Sep 20 | 45 | -4 | 16 | 5 |
| 30 Jun 20 | 44 | -2 | 16 | 4 |
| 31 Mar 20 | 47 | 0 | 16 | 4 |
| 31 Dec 19 | 50 | 2 | 17 | 4 |
| 30 Sep 19 | 50 | 4 | 16 | 4 |
| 30 Jun 19 | 50 | 2 | 17 | 4 |
| 31 Mar 19 | 45 | 0 | 16 | 5 |
| 31 Dec 18 | 45 | 0 | 16 | 5 |
| 30 Sep 18 | 42 | -2 | 16 | 5 |
| 30 Jun 18 | 41 | -2 | 15 | 5 |
| 31 Mar 18 | 45 | -3 | 16 | 5 |
| 31 Dec 17 | 43 | -1 | 16 | 5 |
| 30 Sep 17 | 42 | -2 | 16 | 5 |
| 30 Jun 17 | 42 | 0 | 15 | 5 |
| 31 Mar 17 | 38 | 4 | 13 | 4 |
| 31 Dec 16 | 37 | 4 | 13 | 4 |
| 30 Sep 16 | 41 | 11 | 13 | 4 |
| 30 Jun 16 | 39 | 5 | 12 | 3 |
| 31 Mar 16 | 40 | 2 | 12 | 3 |
| 31 Dec 15 | 35 | -2 | 12 | 3 |
| 30 Sep 15 | 30 | -11 | 12 | 3 |
| 30 Jun 15 | 30 | 2 | 12 | 3 |
Des revenus de qualité: EDAP n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: EDAP n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: EDAP n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 49.6% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de EDAP au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: EDAP n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Medical Equipment ( 14.8% ).
Rendement des fonds propres
ROE élevé: EDAP a un retour sur capitaux propres négatif ( -305.76% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 13:27 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
EDAP TMS S.A. est couverte par 7 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Andrew D'Silva | B. Riley Securities, Inc. |
| null null | CG Capital |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |